← Eichor
Condition: Renal Sclerosis Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Renal Sclerosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

US Zamto-cel Autoimmune Diseases
Phase 1 · 1 location(s) · Miltenyi Biomedicine GmbH · NCT06708845A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1 · 14 location(s) · CRISPR Therapeutics · NCT06925542A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07104721Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
Phase 1/Phase 2 · 1 location(s) · Beijing GoBroad Hospital · NCT06947473CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07305116A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Disease
Phase 1 · 28 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07115745A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With
Phase 1 · 14 location(s) · Allogene Therapeutics · NCT07085104A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidne
NA · 2 location(s) · St. James's Hospital, Ireland · NCT07561957Sapu003 in Advanced mTOR-sensitive Solid Tumors
Phase 1 · 1 location(s) · SAPU NANO (US) LLC · NCT07369505Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
EARLY_Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07507201A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Phase N/A · 1 location(s) · Kyverna Therapeutics · NCT07403188Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06350110CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
Phase 1/Phase 2 · 1 location(s) · Beijing GoBroad Hospital · NCT06947460National Registry of Rare Kidney Diseases
Phase N/A · 1 location(s) · UK Kidney Association · NCT06065852Observational, Retrospective, Multicenter, Nonprofit Study on the Prevalence of Renal Involvement in Pediatric Patients
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06764602The Validity of the Quick Renal MRI in Pediatric Kidney Disease
NA · 1 location(s) · University of Wisconsin, Madison · NCT03959163Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Di
Phase 1/Phase 2 · 2 location(s) · M.D. Anderson Cancer Center · NCT06434363Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)
Phase N/A · 1 location(s) · Stefan Lujinschi · NCT07575347CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
EARLY_Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07586267A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Phase 1 · 21 location(s) · Fate Therapeutics · NCT06308978
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.